42 results about "Epilepticus status" patented technology

Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, tinnitus, and status epilepticus.

The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and materials for treating seizure and seizure disorders, epilepsy, status epilepticus, migraine, spreading depression, intracranial hypertension; for treating the pathophysiological effects of head trauma, stroke, ischemia and hypoxia; for treating or protecting from the pathophysiological effects of neurotoxic agents such as ethanol; and for treating neurophsyciatric disorders and central nervous system edema by administering agents that modulate ionic concentrations and / or ionic gradients in the brain, particularly ion-dependent or cation-chloride cotransporter antagonists. Electrolyte cotransport antagonists and combinations of such compositions with other agents for treating various conditions are disclosed. The present invention also relates to methods and compositions for treating pain by administering ion-dependent cotransporter antagonists. Methods and compositions for enhancing cortical function, for example, in centers of cognition, learning and memory, by administering ion-dependent cotransporter agonists are disclosed.

The invention provides application of dextro-oxiracetam in preparation of drugs for prevention or treatment of epilepsy. Experimental results show that dextro-oxiracetam has obvious treatment effect on generalized epilepsy seizure, partial epilepsy seizure and status epilepticus.

A novel method of vehicle modulated administration of an anticonvulsive agent to the mucous membranes of humans and animals is disclosed. The vehicle system is an aqueous pharmaceutical carrier comprising an aliphatic alcohol (10–80%) or a glycol (10–80%), and their combinations with a biological surfactant such as a bile salt or a lecithin. The pharmaceutical composition provides a means to control and promote the rate and extent of transmucosal permeation and absorption of the medicaments via a single and multiple administration. Nasal administration of the pharmaceutical preparation produces a high plasma concentration of the anticonvulsant nearly as fast as intravenous administration. Such compositions are particularly suitable for a prompt and timely medication of patients in the acute and / or emergency treatment of status epilepticus and other fever-induced seizures.

This invention relates generally to pharmaceutical compositions for treating seizures, and, more particularly, to pharmaceutical compositions that are bioadherent to oral and / or nasal mucosa, comprise one or more anti-acute seizure agents, and can be used to treat one or more conditions selected from the group consisting of acute seizure, repetitive seizures, and status epilepticus. This invention also relates generally to methods for preparing such compositions, methods of treatment using such compositions, uses of such compositions to prepare medicaments, and kits comprising such compositions.

Novel acyl-urea containing compounds, processes of preparing same, compositions containing same and uses thereof in the treatment of neurological diseases and disorders such as epilepsy, neuropathic pain, bipolar disorder, status epilepticus, chemically-induced convulsions and / or seizure disorders, febrile convulsions conditions, metabolic disturbances and a sustenance withdrawal conditions, are provided. Also provided are uses of these and other acyl-urea containing compounds in the treatment of neurological diseases and disorders.

The invention relates to the use of cyclic Prolyl Glycine (“cyclic PG” or “cPG”) and analogs and mimetics thereof, as neuroprotective agents for the treatment and or prevention of neurological disorders including but not limited to cerebral ischemia or cerebral infarction resulting from a range of phenomena, such as thromboembolic or hemorrhagic stroke, cerebral basospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia such as from drowning, pulmonary surgery, and cerebral trauma, as well as to the treatment and prevention of chronic neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, and as anticonvulsants.

The present invention is directed to a pharmaceutical composition comprising a Compound (a) of a class of peptide Compounds and at least one further Compound (b) for the prevention, alleviation or / and treatment of epileptic seizures.

The invention belongs to the field of pharmaceutical preparations, and in particular relates to the application of barisenoside B (PB) in the preparation of drugs for preventing or treating epilepsy induced by pilocarpine (PILO). For the first time, it was found that barisenoside B can significantly prolong the latency period of pilocarpine-induced epilepsy, shorten the duration of status epilepticus, reduce the grade of epileptic seizures, and slow down the weight loss caused by epilepsy, so it has a good effect on PILO-induced epilepsy Preventive and therapeutic effects. It has important clinical application value in pilocarpine-induced epilepsy, and at the same time opens up a new drug use for the active ingredient of barisonoside B.

The present invention provides a novel pyrimidine compound represented by Formula [I] and a salt thereof:[in the formula, the symbols are as defined in the specification], which is useful for treating, preventing and / or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.

The present invention provides a novel heterocyclic compound represented by Formula [I] and a salt thereof: wherein the symbols are as defined in the specification, which is useful for treating, preventing and / or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.